Menu
Search
|

Menu

Close
X

Novocure Ltd NVCR.OQ (NASDAQ Stock Exchange Global Select Market)

31.04 USD
+0.56 (+1.84%)
As of 1:35 PM EST
chart
Previous Close 30.48
Open 30.35
Volume 93,015
3m Avg Volume 237,806
Today’s High 31.09
Today’s Low 29.90
52 Week High 53.70
52 Week Low 17.45
Shares Outstanding (mil) 93.01
Market Capitalization (mil) 2,919.70
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
178
FY17
177
FY16
83
FY15
33
EPS (USD)
FY18
-0.526
FY17
-1.087
FY16
-1.544
FY15
-2.034
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
12.58
22.95
Price to Book (MRQ)
vs sector
25.40
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
129.84
15.47
LT Debt to Equity (MRQ)
vs sector
129.84
11.13
Return on Investment (TTM)
vs sector
-38.33
13.00
Return on Equity (TTM)
vs sector
-80.88
14.69

EXECUTIVE LEADERSHIP

William Doyle
Executive Chairman of the Board, Since 2016
Salary: $750,000.00
Bonus: --
Asaf Danziger
Chief Executive Officer, Director, Since 2012
Salary: $698,439.00
Bonus: --
Kinyip Leung
Vice Chairman of the Board, Since
Salary: --
Bonus: --
Wilhelmus Groenhuysen
Chief Financial Officer, Since 2012
Salary: $600,600.00
Bonus: --
Michael Ambrogi
Chief Operating Officer, Since
Salary: $381,225.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Forum, NO. 4 Grenville Street
SAINT HELIER     JE2 4UF

Phone: +441534.756700

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

SPONSORED STORIES